Annual Report for FY: 2025-26 is attached.

Gujarat Terce Laboratories Ltd The Journey to the Shelf A prescription is an intention. Availability makes it real. A doctor’s trust produces a prescription. That prescription becomes medicine only when the brand is waiting on the shelf in the patient’s own town on the day it is needed. Distribution is the bridge between a doctor’s confidence and a patient’s recovery. Gujarat Terce has built that bridge since 1985, one relationship at a time. Today, 385 stockists carry its brands to more than 22,000 retail outlets across 224 districts in 13 states. The network reaches urban, semi-urban and rural markets alike, including places where supply chains stay fragile. It was built city by city, taluka by taluka, on consistent delivery and dependable service. These relationships stay healthy, and the numbers show it. Collections have quickened as trust has deepened, with debtor days falling under 37. A new entrant would need five to seven years to reach this level. The doctor creates the prescription. Distribution carries it home. 22,000+ 385 Retail Outlets Stockists 224 13 1985 Since Districts States Built grounds-up Corporate Overview Statutory Report Financial Statements Where Relationships Become Brands A brand is a relationship made visible. When a doctor trusts, a chemist stocks and a patient returns, a name begins to carry meaning. Repeated across years and geographies, that meaning becomes a brand. This is how Gujarat Terce has built its portfolio of 50 brands across 125 products and 10 therapeutic areas. The proof sits at the front of the range. TYNOL carries 25 years of paediatric trust, grew 14% in value to D5.75 crore, and compounds at 19.3% over five years. ACOLATE, the respiratory anchor at D8.60 crore, lives in thousands of practices where one generation of doctors taught the next to prescribe it. VITFOL deepens in nutrition. LASOKID and HYTERCE show the engine still creates new franchises. Each brand returns to strengthen the relationship that made it, and the doctor prescribes with even greater confidence. The flywheel turns once more. Relationships build brands. Brands deepen relationships. Forty years prove it. 50/125 10 Brands and Therapeutic products areas 10 25+ 19.3% D Cr Yrs TYNOL Doctors’ TYNOL (FY27 ambition) Trust (5-yr CAGR) Annual Report 2025-26 05 For more than 25 years, TYNOL has been a trusted companion in pediatric care, building strong relationships with healthcare professionals through consistent quality, dependable outcomes, and widespread availability. What began as a product offering has evolved into one of Gujarat Terce’s most important brand franchises, creating lasting confidence among doctors and caregivers alike. Today, TYNOL stands at the intersection of heritage and opportunity. Supported by an expanding portfolio, growing doctor acceptance, and renewed strategic focus, the brand is positioned to play a pivotal role in the Company’s next phase of growth. Why TYNOL Matters The pediatric segment remains one of the most relationship-driven categories within pharmaceuticals. Doctors continue to value brands that demonstrate consistency, efficacy, and reliability over time. TYNOL’s enduring acceptance reflects Gujarat Terce’s ability to build and sustain these relationships. Its strong market presence, combined with increasing product visibility and focused field execution, has enabled the brand to maintain relevance in a competitive landscape while continuing to expand its growth potential. )hkaL euneveR Corporate Overview Statutory Report Financial Statements Element Content Positioning “The Next Big Thing” Heritage 25+ years of doctor trust 5-year CAGR 19.30% ~D5.75 crore for the TYNOL group with positive value and FY26 value achievement unit growth. Flagship SKU Tynol MF Forte — highest-value SKU in the portfolio. Tynol IB Suspension 100 ml exceeded FY26 target by 17% Breakout SKU and delivered strong growth. FY27 ambition D10 crore brand aspiration Annual Report 2025-26 07 For more than two decades, ACOLATE has earned the trust of doctors and medical practitioners far and wide. Today, it remains one of Gujarat Terce’s most recognised and established franchises, serving both paediatric and physician segments through a comprehensive portfolio of respiratory solutions. A Foundation Built Through Relationships ACOLATE’s success reflects years of scientific engagement, doctor education, and consistent market presence. By remaining closely connected to healthcare professionals and understanding evolving patient needs, Gujarat Terce has nurtured the brand into a trusted respiratory franchise across multiple markets. Acolate Plus contributed approximately D2 crore in FY25 and approximately D1 crore in FY26, following regulatory changes affecting fixed-dose combinations, accounting for substantially all of the franchise’s revenue decline. The underlying franchise, excluding this impact, held firm. The Company’s strategy for FY27 focuses on strengthening growth across the most promising components of the franchise: ACOLATE DS ACOLATE KID ACOLATE AF By concentrating resources on these high-potential products, Gujarat Terce aims to reinforce ACOLATE’s leadership position while unlocking new growth opportunities. Element Content Positioning “The Respiratory Anchor” Heritage 25+ years of prescription history 8 SKUs across paediatric and physician respiratory use Portfolio cases FY26 value achievement ~D8.60 crore ACOLATE PLUS impacted by FDC regulatory changes, Challenge acknowledged reducing contribution. Prioritise DS, KID, AF, and physician SKUs while resolving FY27 focus the PLUS pathway. )hkaL euneveR Gujarat Terce Laboratories Ltd Over the years, VITFOL has evolved into a trusted nutritional franchise serving patients across different life stages—from paediatric care to maternal wellness and general nutritional supplementation. Supported by a diversified four-product portfolio and a five- year CAGR of 12.4%, the brand continues to play an important role within Gujarat Terce’s healthcare offering. As the Company sharpens its focus on physician engagement and prescription conversion, VITFOL is well-positioned to strengthen its contribution in the years ahead. Brand Highlights  4-product franchise  12.4% 5-year CAGR  Presence across paediatric, maternal and physician segments  Significant opportunity for deeper physician penetration )hkaL euneveR Corporate Overview Statutory Report Financial Statements Annual Report 2025-26 09 Over the years, FERLIT has strengthened its position as a trusted women’s health brand, building enduring relationships with gynaecologists and supporting women across critical stages of care. As one of Gujarat Terce’s established franchises, the brand continues to play an important role in the Company’s maternal and women’s wellness portfolio. With a focused approach towards strengthening doctor engagement and improving prescription momentum, FERLIT is positioned to regain growth and reinforce its leadership within the gynaecology segment. FY27 Focus Recovery and prescription growth through intensified field engagement. Brand Highlights  Established women’s health franchise  Strong relationships across gynaecology specialists  Core contributor within maternal wellness portfolio  Significant opportunity for deeper prescription conversion )hkaL euneveR Gujarat Terce Laboratories Ltd RESPLASH has evolved into an important growth platform within Gujarat Terce’s physician and general medicine portfolio. The brand supports the Company’s strategy to expand beyond paediatric nutrition and strengthen its engagement across broader physician- led healthcare segments. Backed by increased doctor outreach and sharper prescription conversion initiatives, RESPLASH is well-positioned to enhance penetration and drive sustainable growth in the years ahead. FY27 Focus Expanding physician coverage and improving prescription conversion. Brand Highlights  Strategic presence in physician/general medicine segm [Showing first 8,000 characters — download PDF for full document]